Regulonix Holding, Inc., a Tucson based biotechnology start-up company focused on developing non-opioid therapeutics to relieve chronic pain, recently formed a Scientific Advisory Board (SAB) to provide pre-clinical development guidance for the company’s internationally-patented lead compounds.
Read More ›
July, 2018 Non-opioid pain therapeutics company Regulonix Raises $2 Million in Seed Funding Led by UAVenture Capital Fund
Regulonix Holding, Inc., a University of Arizona biotechnology start-up company focused on developing non-opioid therapeutics to relieve chronic pain, today announced seed investment of $2 million.
Learn More ›
November, 2017 Regulonix Licenses Non-Opioid Pain Drug Candidates
Regulonix has invented and licensed a new class of non-opioid compounds that have been shown in animal models to be more effective than morphine, non-addictive, and non-toxic.
Read More ›
UAVenture Capital Fund LLC, the Tucson-based early-stage capital fund dedicated to the commercialization of University of Arizona science and technology, has announced its first three portfolio investments.Learn more ›
June, 2018 Arizona Daily Star business and technology news
A new, early stage venture capital firm aimed at supporting University of Arizona technology spinoffs has made its first three investments.Read article here ›
January, 2018 Regulonix Featured in Tucson Tech
A recent article in the Arizona Daily Star details the successes and future plans of Tech Launch Arizona. TLA is in its 5th year of supporting start-ups at the University of Arizona. Regulonix is featured in the article.Read article here ›
September, 2017 San Diego Showcase
Look for Regulonix at the San Diego Innovation Showcase October 26, 2017Learn more ›
May, 2017 Phase I Funding
Regulonix has received a 12-month Phase I STTR grant from the National Institutes of Health for “Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates”Read more ›